Trial NCT03715153

View at ClinicalTrials.gov 
Org. Study IDs: CL3-95008-002
Secondary IDs: 2017-004420-30

Last trial update was posted on 2023-06-05

MeSH Interventions

Bumetanide

MeSH Conditions

Autism Spectrum Disorder Autistic Disorder Child Development Disorders, Pervasive

Other Conditions

Autism Spectrum Disorder (ASD)

Stopping Reasons

The 6-month efficacy analysis did not show any significant difference between bumetanide versus placebo in the treatment of ASD in the overall studied population. No unexpected safety concerns were identified.

Limitations And Caveats

The sponsor decided to stop the S95008 development and prematurely discontinue the extension period. This decision was not related to unexpected safety concerns.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID